-
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
•
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price bidding for the National Reimbursement Drug List (NRDL) adjustment at a press conference scheduled for 10:00 am on November 28th. This event marks a significant moment in the healthcare sector as it will disclose the…
-
China’s NHSA Concludes Pre-Negotiation Talks for National Reimbursement Drug List
•
According to the Economic Observer, an independent Chinese weekly newsletter, a series of discussions preceding the National Reimbursement Drug List (NRDL) price negotiation occurred from October 16 to 18. These pre-negotiation talks, which serve as one-on-one communications prior to the formal negotiation process, were divided into three groups this year.…
-
NHSA Updates NRDL Review, Adds Three Domestic Western Medicines
•
The National Healthcare Security Administration (NHSA) has issued a notification regarding the review and correction of results related to drugs on the preliminary formal review list of the National Reimbursement Drug List (NRDL). This update follows feedback collected from August 7 to 13, 2024. The revised list now includes 249…
-
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
•
The Department of Health and Human Services (HHS) in the US has released a list of the first 10 medicines that will be subject to a novel mechanism for negotiating drug prices under the Medicare health insurance program starting from the 2026 period onwards. The institution plans to publish the…
-
Antengene’s Xpovio Price Reduced by 37% in China, Aiding Patient Access
•
Antengene Corp., Ltd (HKG: 6996) has announced a significant price reduction for its drug Xpovio (selinexor) in China, cutting the cost by 37%. The new pricing for the 20mg*12 tablet box is RMB 14,135, and for the 20mg*16 tablet/box, it is RMB 18,649.67, down from the previous prices of RMB…
-
AstraZeneca Challenges US Government’s Drug Price Negotiation Plan for Medicare
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has filed a legal claim against the US government’s plan to negotiate the price of selected drugs for the 2026 period onwards through the elderly health insurance program, Medicare. This move makes AstraZeneca the fourth company to contest the initiative this year, following…
-
NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments
•
The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have passed the preliminary formal review stage for potential inclusion in this year’s adjustment to the National Reimbursement Drug List (NRDL). The public feedback window is open from August 18 to 24, 2023, allowing stakeholders to…
-
NHSA Releases Official Guidelines for Drug Negotiations and Bidding for NRDL Update
•
The National Healthcare Security Administration (NHSA) has officially released the “Negotiation Drug Renewals” and “Non-exclusive Drug Bidding” guidelines for the annual update to the National Reimbursement Drug List (NRDL). These guidelines outline the processes for drug negotiations and bidding, ensuring transparency and efficiency in the management of drugs included in…
-
Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data
•
The government of Hainan province has entered into a strategic partnership with the National Healthcare Security Administration (NHSA) by signing a memorandum of understanding (MoU). This collaboration aims to enhance the medical insurance industry through the innovative use of real-world data in procurement processes and beyond. Leveraging Real-World Data for…
-
Jiangsu Initiates Price Negotiations for Provincial Stock Drugs, Addresses Shortages
•
The Jiangsu Public Resource Trading Platform has released a notification indicating the commencement of price negotiations for provincial stock drugs on April 27. The initiative involves 18 shortage drugs, including pralidoxime, deslanoside, promethazine, and agkistrodon halys snake antivenom, with the participation of 30 manufacturers such as Beijing China Resources Hi-Tech…
-
China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report
•
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which includes the National People’s Congress and commenced this week in Beijing. The report highlighted significant economic and social advancements, reflecting the government’s efforts in various sectors. Economic HighlightsDuring 2022, China’s national GDP reached RMB 121…
-
China Optimizes Medical Insurance Policies for COVID-19 Treatment
•
The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center for Disease Control and Prevention have released a Notice on “Optimizing Relevant Medical Insurance Policies for Treatment Expenses of Patients with Novel Coronavirus Infection after Implementation of ‘Class B and Class B Management’”. The guidelines…
-
NHSA Launches Expert Review for 2025 NRDL Update in China
•
The National Healthcare Security Administration (NHSA) announced on September 16 the commencement of the expert review process for this year’s National Reimbursement Drug List (NRDL) update. The three-day event, held in Beidaihe, Qinhuangdao, Hebei province, will conclude on September 22. This process is a crucial step in determining which drugs…
-
NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals
•
The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL) Adjustment Work Plan” along with relevant documents. This official update to the draft proposal issued on June 13th outlines the full details and processes for this year’s NRDL update. List Adjustment ScopeThe scope of the…
